SRZN Valuation

Surrozen Inc

Add to Watchlist

Advanced Chart

13.200

-0.54(-3.930%)1D

SRZN Relative Valuation

SRZN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SRZN is overvalued; if below, it's undervalued.

Historical Valuation

Surrozen Inc (SRZN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.83. The fair price of Surrozen Inc (SRZN) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：13.20

Fair

-2.42

Trailing

Forward

0.00

EV/EBITDA

Surrozen Inc. (SRZN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.74. The thresholds are as follows: Strongly Undervalued below -4.81, Undervalued between -4.81 and -2.78, Fairly Valued between 1.29 and -2.78, Overvalued between 1.29 and 3.33, and Strongly Overvalued above 3.33. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.90

EV/EBIT

Surrozen Inc. (SRZN) has a current EV/EBIT of -0.90. The 5-year average EV/EBIT is -0.58. The thresholds are as follows: Strongly Undervalued below -4.40, Undervalued between -4.40 and -2.49, Fairly Valued between 1.33 and -2.49, Overvalued between 1.33 and 3.23, and Strongly Overvalued above 3.23. The current Forward EV/EBIT of -0.90 falls within the Historic Trend Line -Fairly Valued range.

235.54

Surrozen Inc. (SRZN) has a current PS of 235.54. The 5-year average PS is 15.69. The thresholds are as follows: Strongly Undervalued below -93.52, Undervalued between -93.52 and -38.92, Fairly Valued between 70.29 and -38.92, Overvalued between 70.29 and 124.90, and Strongly Overvalued above 124.90. The current Forward PS of 235.54 falls within the Strongly Overvalued range.

0.00

P/OCF

Surrozen Inc. (SRZN) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.51. The thresholds are as follows: Strongly Undervalued below -4.30, Undervalued between -4.30 and -2.90, Fairly Valued between -0.11 and -2.90, Overvalued between -0.11 and 1.28, and Strongly Overvalued above 1.28. The current Forward P/OCF of 0.00 falls within the Overvalued range.

-2.16

P/FCF

Surrozen Inc. (SRZN) has a current P/FCF of -2.16. The 5-year average P/FCF is -0.63. The thresholds are as follows: Strongly Undervalued below -2.43, Undervalued between -2.43 and -1.53, Fairly Valued between 0.27 and -1.53, Overvalued between 0.27 and 1.17, and Strongly Overvalued above 1.17. The current Forward P/FCF of -2.16 falls within the Undervalued range.

Surrozen Inc (SRZN) has a current Price-to-Book (P/B) ratio of -4.81. Compared to its 3-year average P/B ratio of 2.26 , the current P/B ratio is approximately -312.47% higher. Relative to its 5-year average P/B ratio of 1.86, the current P/B ratio is about -358.01% higher. Surrozen Inc (SRZN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -135.51%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -99.32% , the current FCF yield is about -100.00% lower.

-4.81

P/B

Median3y

2.26

Median5y

1.86

-17.86

FCF Yield

Median3y

-135.51

Median5y

-99.32

Competitors Valuation Multiple

The average P/S ratio for SRZN's competitors is 0.00, providing a benchmark for relative valuation. Surrozen Inc Corp (SRZN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -90.17%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Fate Therapeutics Inc

Spruce Biosciences Inc

Prelude Therapeutics Inc

Greenwich Lifesciences Inc

Loss

112.91M

Performance Decomposition

Market capitalization of SRZN increased by 8.20% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -14.34 to -7.29K.

The secondary factor is the Revenue Growth, contributed -90.17%to the performance.

Overall, the performance of SRZN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-90.17%

10.00M → 983.00K

Revenue Growth

50724.27%

-14.34 → -7.29K

Margin Expansion

-50625.90%

0.00 → -0.91

P/E Change

8.20%